In the case of medical equipment, HTA has been carried out on demand -requests of a group interested in the adoption of a new technology-. The CCSS is making efforts to improve this process by implementing an institutional policy of technology assessment, where a multidisciplinary group intervenes proactively and not by demand as is currently done. In the case of drugs, HTA is done in the CCSS at the request of clinicians, medical societies and government agencies, among others, which detect therapeutic grey areas/holes. These requests are supported by evidence to determine whether it can be included in the services or not.